Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- Susan M. Domchek
- , Sophie Postel-Vinay
- , Seock Ah Im
- , Yeon Hee Park
- , Jean Pierre Delord
- , Antoine Italiano
- , Jerome Alexandre
- , Benoit You
- , Sara Bastian
- , Matthew G. Krebs
- , Ding Wang
- , Saiama N. Waqar
- , Mark Lanasa
- , Joon Rhee
- , Haiyan Gao
- , Vidalba Rocher-Ros
- , Emma V. Jones
- , Sakshi Gulati
- , Anna Coenen-Stass
- , Iwanka Kozarewa
- University of Pennsylvania
- Université Paris-Saclay
- Université Paris-Saclay
- Seoul National University
- Sungkyunkwan University
- Institut Universitaire du Cancer de Toulouse
- Centre Georges-François Leclerc
- Université Paris Cité
- Hospices civils de Lyon
- Universite Claude Bernard Lyon 1
- Groupe des Investigateurs Nationaux pour les Cancers de l Ovaire et du sein-GINEGEPS
- Kantonsspital Graubünden
- University of Manchester
- Manchester University NHS Foundation Trust
- Henry Ford Health System
- Washington University St. Louis
- AstraZeneca
- Sheba Medical Center at Tel Hashomer
- Tel Aviv University
Research output: Contribution to journal › Article › peer-review
460
Link opens in a new tab
Scopus
citations